Skip to main content
Erschienen in: Clinical & Experimental Metastasis 3/2009

01.03.2009 | Research Paper

The CXCR4/CXCL12 axis in endometrial cancer

verfasst von: Stefania Gelmini, Monica Mangoni, Francesca Castiglione, Cristina Beltrami, Annalisa Pieralli, Karin Louise Andersson, Massimiliano Fambrini, Gian Luigi Taddei, Mario Serio, Claudio Orlando

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Chemokines and their receptors seem to act as important regulators of the metastatic cascade. CXCL12 and its receptor CXCR4 were shown to be involved in human cancer progression. There is increasing evidences suggesting that the expression of CXCR4 in human cancers is correlated with poor patient prognosis and that CXCR4 neutralization can prevent metastases in vivo. Here we tested the role of the CXCR4/CXCL12 axis in a neoplasia with a reduced risk of metastatic progression, such as human endometrial cancer. CXCR4 and CXCL12 mRNA expression was measured in 41 endometrial cancers and in corresponding not affected tissues. The expression of CXCR4 was predominant in endometrial cancer (= 0.035) whereas CXCL12 was overexpressed in normal mucosae (= 0.002). CXCR4 expression (= 0.035), but not CXCL12, was significantly related to cancer differentiation. Endometrial cancer cells (HEC1A) were able to generate diffuse metastases in peritoneum, lung and liver of CD-1 nude mice, but the simultaneous treatment with a neutralizing anti-CXCR4 monoclonal antibody dramatically reduced the number and the size of metastases in the animals. In conclusion, our data seem to indicate that the CXCR4-CXCL12 axis can play a role in the progression of endometrial carcinoma and that specific therapies with antagonists of chemokines receptors could be of help in the treatment of metastatic patients.
Literatur
2.
3.
Zurück zum Zitat Tsukamoto H, Shibata K, Kajiama H et al (2007) Uterine smoth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clin Exp Metastasis 24:423–429. doi:10.1007/s10585-007-9079-5 PubMedCrossRef Tsukamoto H, Shibata K, Kajiama H et al (2007) Uterine smoth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction. Clin Exp Metastasis 24:423–429. doi:10.​1007/​s10585-007-9079-5 PubMedCrossRef
8.
Zurück zum Zitat Broxmeyer HE, Cooper S, Kohli L et al (2003) Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol (Baltimore, MD: 1950) 170:421–429 Broxmeyer HE, Cooper S, Kohli L et al (2003) Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol (Baltimore, MD: 1950) 170:421–429
16.
Zurück zum Zitat Koizumi K, Kozawa Y, Ohashi Y et al (2007) CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro. Oncology Rep 17:1511–1516 Koizumi K, Kozawa Y, Ohashi Y et al (2007) CCL21 promotes the migration and adhesion of highly lymph node metastatic human non-small cell lung cancer Lu-99 in vitro. Oncology Rep 17:1511–1516
17.
Zurück zum Zitat Kryczek I, Wei S, Keller E et al (2007) Stroma-derived factor (SDF1/CXCL12) and human pathogenesis. Am J Physiol Cell Physiol 292:C987–C995PubMedCrossRef Kryczek I, Wei S, Keller E et al (2007) Stroma-derived factor (SDF1/CXCL12) and human pathogenesis. Am J Physiol Cell Physiol 292:C987–C995PubMedCrossRef
22.
23.
Zurück zum Zitat Sun YX, Fang M, Wang J et al (2007) Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67:61–73. doi:10.1002/pros.20500 PubMedCrossRef Sun YX, Fang M, Wang J et al (2007) Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 67:61–73. doi:10.​1002/​pros.​20500 PubMedCrossRef
24.
Zurück zum Zitat Kajiyama H, Shibata K, Terauchi M et al (2008) Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122:91–99. doi:10.1002/ijc.23083 PubMedCrossRef Kajiyama H, Shibata K, Terauchi M et al (2008) Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 122:91–99. doi:10.​1002/​ijc.​23083 PubMedCrossRef
26.
Zurück zum Zitat Brian XW, Yang SX, Chen JH et al (2007) Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 61:570–578CrossRef Brian XW, Yang SX, Chen JH et al (2007) Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 61:570–578CrossRef
28.
29.
Zurück zum Zitat Oda Y, Yamamoto H, Tamiya S et al (2006) CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19:738–745. doi:10.1038/modpathol.3800587 PubMedCrossRef Oda Y, Yamamoto H, Tamiya S et al (2006) CXCR4 and VEGF expression in the primary site and the metastatic site of human osteosarcoma: analysis within a group of patients, all of whom developed lung metastasis. Mod Pathol 19:738–745. doi:10.​1038/​modpathol.​3800587 PubMedCrossRef
30.
Zurück zum Zitat Shen W, Bendall LJ, Gottlieb DJ et al (2001) The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 29:1439–1447. doi:10.1016/S0301-472X(01)00741-X PubMedCrossRef Shen W, Bendall LJ, Gottlieb DJ et al (2001) The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. Exp Hematol 29:1439–1447. doi:10.​1016/​S0301-472X(01)00741-X PubMedCrossRef
32.
Zurück zum Zitat Cardones AR, Murakami T, Hwang ST et al (2003) CXCR4 enhances adhesion of B16 to endothelial cells tumor cells in vitro and in vivo via beta(1) integrin. Cancer Res 63:6751–6757PubMed Cardones AR, Murakami T, Hwang ST et al (2003) CXCR4 enhances adhesion of B16 to endothelial cells tumor cells in vitro and in vivo via beta(1) integrin. Cancer Res 63:6751–6757PubMed
33.
Zurück zum Zitat Zeelemberg IS, Ruuls-Van Stalle S et al (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63:3833–3839 Zeelemberg IS, Ruuls-Van Stalle S et al (2003) The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 63:3833–3839
34.
Zurück zum Zitat Sun YX, Schmeider A, Yung Y et al (2005) Skeletal localisation and neutralisation of SDF1 (CXCL12/CXCR4) axis blocks prostate cancer metastasis and growth in osseus sites in vivo. J Bone Miner Res 20:318–329. doi:10.1359/JBMR.041109 PubMedCrossRef Sun YX, Schmeider A, Yung Y et al (2005) Skeletal localisation and neutralisation of SDF1 (CXCL12/CXCR4) axis blocks prostate cancer metastasis and growth in osseus sites in vivo. J Bone Miner Res 20:318–329. doi:10.​1359/​JBMR.​041109 PubMedCrossRef
35.
Zurück zum Zitat Burns JM, Summers BC, Wang Y et al (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. JEM 203:2201–2213. doi:10.1084/jem.20052144 CrossRef Burns JM, Summers BC, Wang Y et al (2006) A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. JEM 203:2201–2213. doi:10.​1084/​jem.​20052144 CrossRef
36.
Zurück zum Zitat Kodama J, Hasengaowa, Seki N et al (2007) Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol 28:370–375PubMed Kodama J, Hasengaowa, Seki N et al (2007) Expression of the CXCR4 and CCR7 chemokine receptors in human endometrial cancer. Eur J Gynaecol Oncol 28:370–375PubMed
37.
Zurück zum Zitat Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using Real-Time Quantitative PCR and the 2−ΔΔCt method. Methods (San Diego, CA) 25:402–408. doi:10.1006/meth.2001.1262 Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using Real-Time Quantitative PCR and the 2−ΔΔCt method. Methods (San Diego, CA) 25:402–408. doi:10.​1006/​meth.​2001.​1262
45.
Zurück zum Zitat Scotton CJ, Wilson JL, Milliken D et al (2001) Epithelial cancer cell migration: a role for chemokine receptors. Cancer Res 61:4961–4965PubMed Scotton CJ, Wilson JL, Milliken D et al (2001) Epithelial cancer cell migration: a role for chemokine receptors. Cancer Res 61:4961–4965PubMed
48.
Zurück zum Zitat Gilbert D, Chandler J, McIntyre A et al (2008) Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumors of adults and adolescents. J Pathol 217:94–102CrossRef Gilbert D, Chandler J, McIntyre A et al (2008) Clinical and biological significance of CXCL12 and CXCR4 expression in adult testes and germ cell tumors of adults and adolescents. J Pathol 217:94–102CrossRef
50.
Zurück zum Zitat Suzuki M, Mohamed S, Nakajima T et al (2008) Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 33:113–119PubMed Suzuki M, Mohamed S, Nakajima T et al (2008) Aberrant methylation of CXCL12 in non-small cell lung cancer is associated with an unfavorable prognosis. Int J Oncol 33:113–119PubMed
Metadaten
Titel
The CXCR4/CXCL12 axis in endometrial cancer
verfasst von
Stefania Gelmini
Monica Mangoni
Francesca Castiglione
Cristina Beltrami
Annalisa Pieralli
Karin Louise Andersson
Massimiliano Fambrini
Gian Luigi Taddei
Mario Serio
Claudio Orlando
Publikationsdatum
01.03.2009
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 3/2009
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-009-9240-4

Weitere Artikel der Ausgabe 3/2009

Clinical & Experimental Metastasis 3/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.